SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Study to look at Covid-19 impact on blood cancer patients
Fri May 22nd - A new UK study is to be launched that will examine how patients who receive stem cell transplants for blood cancers and blood disorders react to severe Covid-19 infection. More
'Focus on blood clotting in Covid-19 patients'
Fri May 22nd - There is an urgent need to focus on medications that address dangerous blood clotting in Covid-19 patients, according to a leading haematologist. More
Immunotherapy hope for elimination of leukaemia stem cells
Fri May 22nd - Hematopoietic stem cells can be selectively eliminated using immunotherapy instead of chemotherapy, a new Swiss study has revealed. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Out-patient procedure improves condition of type 2 diabetes patients

Tuesday March 31st, 2020

A novel out-patient procedure helped to improve blood glucose levels, liver insulin sensitivity, and other metabolic measures in people with poorly controlled type 2 diabetes, researchers reported last night.

The procedure centres on "resetting" the duodenum, reducing insulin resistance, developers say.

Research, which was due to be presented at the Endocrine Society’s now cancelled annual meeting, found that patients who were treated with Revita duodenal mucosal resurfacing (DMR), a novel, minimally invasive, endoscopic procedure, showed the improvements up to three months later.

The REVITA-2 study, a randomised, sham-controlled clinical trial, has helped researchers verify the insulin sensitising mechanism by which hydrothermal ablation of the duodenum improves blood sugar in patients with type 2 diabetes.

Dr David Hopkins, director of the Institute of Diabetes, Endocrinology and Obesity, King's Health Partners in London, UK, said: “This out-patient procedure is being studied as the first disease-modifying therapy for type 2 diabetes and has thus far been demonstrated to be safe, effective, and durable through at least two years of follow up.”

The research team explored the insulin-sensitising mechanisms underlying the previously reported beneficial effects of the Revita DMR therapy.

The technology involves inserting a balloon catheter through the mouth and into the duodenum to precisely deliver thermal energy to the duodenal lining. Once treated, the damaged duodenal lining is flushed out, and a new mucosal layer begins to regenerate.

Dr Hopkins said: “The thickening of the duodenal mucosa occurs early in diabetes and may initiate changes in hormonal signalling that lead to insulin resistance, the main factor leading to type 2 diabetes.

“By resurfacing the mucosa with the Revita DMR technique and effectively resetting this signalling, we are able to demonstrate a reduction of the insulin resistance underlying diabetes and associated metabolic complications.”

The researchers analysed data from 70 patients (blinded: 35 treated; 35 sham) who had a meal tolerance test before and 12 weeks after a single endoscopic procedure. The patients' blood glucose levels were measured before the test, while fasting, and afterwards.

The patients who received Revita DMR had a significantly improved glucose response and had improved liver measures.

Although the average fasting glucose level dropped by only 15mg/dL in the sham group, it fell by 41 mg/dL in the DMR-treated group.

Dr Hopkins said: “These findings confirm that the duodenum is an important therapeutic target for type 2 diabetes.

“The Revita treatment has the potential to transform the lives of patients who cannot adequately control their disease with drug therapies or who are interested in a non-drug treatment alternative that targets the root cause of metabolic disease.”

Tags: Diabetes | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES